comprehensive -WSS

comprehensive

author：focus 2025-09-06 10:33:06 Page View：32

Senate Health, Education, Labor, and Pensions Chair Sen. Bernie Sanders, I-Vt., points toward a poster detailing what he said the U.S. versus the "Rest of the World" spends on prescription drugs, during a hearing to examine the cost of prescription drugs. -- health policy coverage — Sen. Bernie Sanders (I-Vt.) raises his hand at a Thursday hearing on Capitol Hill in Washington to examine the cost of prescription drugs. Jacquelyn Martin/AP

WASHINGTON — Call it Sen. Bernie Sanders’ prescription drug pricing theater.

The hearing, featuring Merck CEO Robert Davis, Johnson & Johnson CEO Joaquin Duato, and Bristol Myers Squibb CEO Chris Boerner, was designed to draw public interest, and in that respect, it worked. The wood-paneled hearing room in a Senate office building was standing room only, with an overflow room prepared. Photographers flocked for photos as Sanders shook hands with each executive, standard practice before such hearings begin.

Sanders’ staff got an arm workout switching out foam boards behind the chairman’s head, illustrating how the drug companies called to testify make more revenue from the United States on certain medications than the rest of the world combined.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drinking less cuts risk of oral cavity, esophageal cancer: Report
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

focus

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

AstraZeneca stays mum on Medicare drug pricing negotiations

AstraZenecaCEOPascalSoriotJacquelynMartin/APLONDON—Medicare’sfirst-everdrugpricingnegotiationsareoff

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Why Novartis is going to walk from its acquisition of MorphoSys

MollyFerguson/STATNovartissaidMondaythatitintendstobuyMorphoSysforjustunder$3billion.Thedealwillnotc